(AOF) – Aelis Farma (-49.12% at 5.80 euros) collapsed after the failure of the phase 2B clinical study carried out with its product AEF0117, which aims to reduce cannabis consumption. This clinical-stage biotech specializing in the development of treatments for brain diseases specifies that the primary evaluation criterion, namely the proportion of participants who reduced their cannabis consumption to 1 day per week or less, did not “show significant differences between AEF0117 and the placebo”.
Aelis Farma adds that secondary endpoints measuring the proportion of participants achieving complete abstinence or reducing cannabis use to 2 days per week or less also showed no significant differences between AEF0117 and placebo.
The biotech company notes, however, that at the highest dose of AEF0117 (1 mg/day), “encouraging and consistent positive trends were observed across multiple quantitative endpoints measuring total cannabis consumption.” Some of these declines were even statistically significant in participants with moderate CUD (cannabis abuse).
“It is worth noting that the placebo effect was very small for these criteria, suggesting that in this study, participants with CUD may be resistant to changing the number of days of consumption per week,” Aelis explains, however.
“Aelis Farma continues to study the results of the study in order to determine the best strategic and regulatory action plan,” announces the company which, after completing a capital increase of 4 million euros in August 2024, should be able to finance its activities until the fourth quarter of 2026.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from sources it considers the most reliable. However, the reader remains solely responsible for their interpretation and the use of the information made available to him. Thus, the reader must hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article? Share it with your friends using the buttons below.
